Chief Executive Officer
Dr. Joshi has 20+ years of experience in drug development and has actively contributed to various drug delivery products from new chemical entities to drug delivery applications. He has held senior positions at Elan, Alkermes, ALZA (J&J), and also served as the Co-Founder of Incline Therapeutics (acquired by The Medicines Company).
Director, Product Development
Dr. Shevachman has 14+ years of experience in drug development, commercial manufacturing, and expanding product portfolio. She has a wide experience in drug product submission with a proven record of FDA approvals. She joined the CAGE Bio team in 2018. Prior to joining CAGE, she held senior-level scientist positions at Perrigo and Allergan.
Senior Research Scientist, Product Development
Dr. Mandal joined the CAGE Bio team in 2020 after completing his postdoctoral training from Harvard University, which was primarily focussed on understanding ionic liquid (IL)-based frameworks for delivering nucleic acids transdermally. He received his Ph.D. in Pharmaceutical Sciences from the University of Missouri, Kansas City.
Kevin joined CAGE Bio in 2019 bringing 4+ years of formulation and transdermal research to the team. He has worked on various drug delivery technologies and holds transdermal drug delivery patents. Kevin received his B.S. in Chemistry from the University of California, Santa Barbara. Prior to joining CAGE, Kevin worked at Chrono Therapeutics.